Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from DocMorris ( (CH:DOCM) ).
DocMorris has received an extension for its CardLink solution approval from gematik until January 2027, facilitating a smooth transition to the new PoPP technology for e-prescription redemption. This extension allows patients to continue using their electronic health cards and the DocMorris App without disruption, ensuring continuity in digital healthcare services and reinforcing DocMorris’s position in the digital health market.
The most recent analyst rating on (CH:DOCM) stock is a Buy with a CHF10.00 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.
More about DocMorris
DocMorris AG is a leading Swiss company in the online pharmacy, marketplace, and professional healthcare sectors, with a strong presence in Germany and other European countries. It operates a highly automated logistics center in the Netherlands and is a major player in the health and care product marketplaces in Southern Europe. DocMorris aims to create a digital health ecosystem, serving over 10 million active customers with a wide range of products and services.
Average Trading Volume: 496,884
Current Market Cap: CHF336.9M
For a thorough assessment of DOCM stock, go to TipRanks’ Stock Analysis page.